Effect of Circulating Omentin-1 on the Retinal Circulation in Patients With Type 2 Diabetes Mellitus

Omae, Tsuneaki; Nagaoka, Taiji; Yoshida, Akitoshi

doi:10.1167/iovs.17-22030

Cited by 7 publications

(3 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Korany et al (23) also found that, serum omentin-1 level was significantly lower in diabetic patients compared with the control, and in DR compared with diabetics without DR. Omae et al (24) also found that, serum omintin-1 was reduced significantly (P<0.001) in DR patients, comparing with DM patients without retinopathy. Additionally, in recent meta-analysis study showed that serum level of omentin was significantly lower in T2DM compared to healthy controls (25) .…”

Section: Discussionmentioning

confidence: 84%

Study the Role Serum Omentin-1 in Occurrence and Development of Diabetic Retinopathy

2020

MLU

View full text Add to dashboard Cite

Diabetic retinopathy (DR) is a retinal disease which is one of the most severe micro vascular complications occurring due to diabetes mellitus and is a major cause of blindness. The aim of this work was to study the serum level of omentin-1 and its relation to diabetic retinopathy in type 2 diabetes mellitus. The study included 60 diabetic patients (30 patients T2DM complicated with DR and 30 patients T2DM not complicated with DR). The study also included 30 healthy control individuals defended as subjects who apparently haven't any chronic diseases. Thorough history taking and physical examination with calculation of body mass index (BMI), investigations were done including HbA1c, C-reactive protein (CRP) and serum omentin-1. Fundus examination was carried out by an expert ophthalmologist. The study showed that serum omintin-1 was reduced significantly (P<0.001) in DM patients (15.29±3.69 ng/ml) as compared with the control group (24.95±4.22 ng/ml), Table 1. The study also showed that serum omintin-1 was reduced significantly (P<0.001) in DR patients (12.39±2.21 ng/ml), comparing with DM patients without retinopathy (17.52±2.28 ng/ml). The study revealed that the highest mean of HbA1c was found in DM patients (8.39±1.62 %) as compared by the control group (4.91±0.43 %) (P<0.001), Table 3. The study also found that HbA1c was elevated significantly (P<0.001) in DR patients (9.38±1.65 %) comparing with DM patients without retinopathy (7.66±0.79 %) (P<0.001). The study showed that, the highest mean of serum CRP was recorded in DM patients (7.89±1.76 mg/dl), as compared with the control group (4.51±0.72 mg/ dl) (P<0.001), Table 5. The study also found that CRP was elevated significantly (P<0.001) in DR patients (9.37±1.11 mg/dl) as compared with diabetic without retinopathy patients (6.41±0.73 mg/dl), The study showed that 60% DR patients suffered from T2D for more than 9 years and 40% suffered DM for 7-9 years while all diabetic patients without retinopathy were suffered from T2D for ≤ 9 years with a significant relation between Dr and the duration of diabetes (P<0.001). The study showed negative correlation of serum omentin-1 concentrations with duration of diabetes, BMI, HbA1c and CRP. From this study we can conclude that serum omentin-1 levels are correlated with the presence and severity of DR.

show abstract

Section: Discussionmentioning

confidence: 84%

Study the Role Serum Omentin-1 in Occurrence and Development of Diabetic Retinopathy

2020

MLU

View full text Add to dashboard Cite

show abstract

“…Furthermore, it was revealed that the serum omentin-1 level was significantly lower in diabetic patients compared to controls and in diabetics with DR compared to diabetics without DR (Abdelraouf Korany et al, 2018). Additionally, it was found that serum omentin-1 levels were considerably lower in DR patients compared to DM patients without retinopathy (Omae et al, 2017). Additionally, recent metaanalysis research found that T2DM patients had significantly lower serum omentin-1 levels than healthy controls (As, 2019).…”

Section: Relation Of Serum Omentin-1 With Diabetic Retinopathymentioning

confidence: 99%

Role of omentin 1 and IL-6 in type 2 diabetes mellitus patients with diabetic retinopathy

Majeed

Al-Ani

Alsabti

2022

ijhs

View full text Add to dashboard Cite

The study included 60 diabetic patients (30 patients type 2 diabetes mellitus complicated with diabetic retinopathy (DR) and 30 patients T2DM not complicated with DR). The study also included 30 healthy control individuals defended as subjects who apparently haven’t any chronic diseases. investigations were done including IL-6 and serum omentin-1. Fundus examination was carried out by an expert ophthalmologist. The study showed that the lowest mean of serum omentin-1 was recorded (P<0.05) in DR patients (687 pg/ml), and the highest (P<0.05)was in the control group (3540.625 pg/ml), The study also demonstrated that there was a significant decrease (P<0.05) in DM patients (991.2 pg/ml). The study also showed that serum IL-6 was increased significantly(P<0.05) in DR patients (253.7 pg/ml) as compared with the control group (35.33 pg/ml), The study also showed that serum IL-6 was increased significantly (P<0.05) in DM patients (102.5 pg/ml). The study showed negative correlation of serum omentin-1 concentrations with IL-6 in DR patients.

show abstract

“…If both eyes had equal retinopathy, one eye was randomly assigned to the study. Patients with other ocular disease, such as glaucoma or retinal vessel occlusion, a history of laser treatment or intraocular surgery, moderate-to-severe cataract, previous ocular inflammation, clinically significant macular edema, and moderate-to-high refractive error (± >3.0 D) were excluded [14,15].…”

Section: Subjectsmentioning

confidence: 99%

Effect of insulin treatment on pulsatility ratio and resistance index of the retinal artery in patients with type 2 diabetes

et al. 2021

Self Cite

View full text Add to dashboard Cite

This study aimed to evaluate whether long-term insulin treatment is associated with abnormalities in retinal circulation in type 2 diabetic patients. We evaluated 19 eyes of nondiabetic individuals and 68 eyes of type 2 diabetic patients. The eyes of diabetic patients were classified into two groups according to the presence or absence of long-term insulin therapy. We used a Doppler optical coherence tomography flowmeter to measure diameter, velocity, and blood flow in the major temporal retinal artery. The pulsatility ratio (PR) and resistance index (RI), indices of vascular rigidity, were calculated from the blood velocity profile. PR and RI were significantly elevated in type 2 diabetic patients compared with nondiabetic subjects (P < 0.05). In type 2 diabetes patients, PR and RI were significantly higher in patients receiving long-term insulin treatment than in those without (P < 0.01). There was a significant difference in velocity (P < 0.05), but not diameter and blood flow, between nondiabetic subjects and type 2 diabetes patients. No significant difference in diameter, velocity, or blood flow was observed between the groups with and without long-term insulin treatment. Long-term insulin treatment can affect PR and RI, which might be associated with vascular rigidity of the retinal artery in patients with type 2 diabetes.

show abstract

Effect of Circulating Omentin-1 on the Retinal Circulation in Patients With Type 2 Diabetes Mellitus

Abstract: Increased concentrations of plasma omentin-1 might be linked to elevated RBF levels probably through elevated blood velocity in patients suffering from type 2 diabetes with incipient DR, especially in female patients, which warrants further investigation.

Cited by 7 publications

References 47 publications

Study the Role Serum Omentin-1 in Occurrence and Development of Diabetic Retinopathy

Study the Role Serum Omentin-1 in Occurrence and Development of Diabetic Retinopathy

Role of omentin 1 and IL-6 in type 2 diabetes mellitus patients with diabetic retinopathy

Effect of insulin treatment on pulsatility ratio and resistance index of the retinal artery in patients with type 2 diabetes

Contact Info

Product

Resources

About